TerminatedNCT00622245
Efficacy and Safety of Lu AA34893 in Patients With Depression in bipolarity
Researchers are comparing Lu AA34893 and placebo to find out how the approaches affect depression symptoms in people with bipolarity type I or II.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
Researchers are comparing Lu AA34893 and placebo to find out how the approaches affect depression symptoms in people with bipolarity type I or II.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Brisbane and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJanuary 2008
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 166
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Australia, France, Canada, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00622245
- Official title
Show the full official title
Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder
Recruitment & locations
TerminatedBrisbane, Australia · Dandenong, Australia · Malvern, Australia
44 more locations
- Vienna, Austria
- Brussels, Belgium
- Charleroi, Belgium
- Diest, Belgium
- Stara Zagora, Bulgaria
- London, Canada
- Montreal, Canada
- Orléans, Canada
- Clermont-Ferrand, France
- Orvault, France
- Paris, France
- Sartrouville, France
- Berlin, Germany
- Bochum, Germany
- Gelsenkirchen, Germany
- Kaunas, Lithuania
- Kaunas Region, Lithuania
- Klaipėda, Lithuania
- Vilnius, Lithuania
- Klang, Malaysia
- Kota Kinabalu, Malaysia
- Kuala Lumpur, Malaysia
- Las Piñas, Philippines
- Mandaluyong, Philippines
- Mandaue City, Philippines
- Gdansk, Poland
- Arad, Romania
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
- Bratislava, Slovakia
- Prešov, Slovakia
- Inchon, South Korea
- Jeonju, South Korea
- Kyunggi-do, South Korea
- Seoul, South Korea
- Halmstad, Sweden
- Lund, Sweden
- Malmö, Sweden
- Sollentuna, Sweden
- Stockholm, Sweden
- Taichung, Taiwan
- Lviv, Ukraine
- Oxford, United Kingdom
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing Lu AA34893 and placebo to find out how the approaches affect depression symptoms in people with bipolarity type I or II.
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Does this study involve medication?
Yes. The study involves medication, including Lu AA34893, Quetiapine fumarate and Placebo.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolarity type I (Bipolar I Depression).